Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002)
Condition(s):Myelofibrosis; Chronic Myelomonocytic Leukemia; Acute Myeloid LeukemiaLast Updated:March 10, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Myelofibrosis; Chronic Myelomonocytic Leukemia; Acute Myeloid LeukemiaLast Updated:March 10, 2023Recruiting
Condition(s):Hematologic Malignancy; AML; ALL; BPDCN; MDS; Lymphoblastic Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Hodgkin Lymphoma; Mixed Phenotype Acute Leukemia; Acute Undifferentiated LeukemiaLast Updated:February 22, 2024Recruiting
Condition(s):Blastic Plasmacytoid Dendritic Cell NeoplasmLast Updated:August 31, 2023Completed
Condition(s):Acute Myeloid LeukemiaLast Updated:March 8, 2024Withdrawn
Condition(s):Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2; Myelodysplastic/Myeloproliferative NeoplasmLast Updated:March 27, 2024Recruiting
Condition(s):Recurrent Adult Lymphoblastic Lymphoma; Recurrent B Acute Lymphoblastic Leukemia; Recurrent T Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia; Refractory Lymphoblastic Lymphoma; Refractory T Acute Lymphoblastic LeukemiaLast Updated:October 16, 2023Recruiting
Condition(s):Blastic Plasmacytoid Dendritic Cell NeoplasmLast Updated:March 22, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.